Selective inhibition of tumor oncogenes by disruption of super-enhancers - Wikidata - awgldk - TriplyDB

Selective inhibition of tumor oncogenes by disruption of super-enhancers

Selective inhibition of tumor oncogenes by disruption of super-enhancers

http://www.wikidata.org/entity/Q29617301

about

The basal transcription machinery as a target for cancer therapy Enhancer activation requires trans-recruitment of a mega transcription factor complex Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer?Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Strategically targeting MYC in cancer The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations Effects of the lifestyle habits in breast cancer transcriptional regulation Epigenetic modulators, modifiers and mediators in cancer aetiology and progression Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer EZH2 in normal hematopoiesis and hematological malignancies Transcriptional enhancers: functional insights and role in human disease MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management Architectural and Functional Commonalities between Enhancers and Promoters SMC complexes link gene expression and genome architecture The Mediator complex: a central integrator of transcription KATs in cancer: functions and therapies Super-enhancers: Asset management in immune cell genomes Enhancer malfunction in cancer Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia Chromatin targeting drugs in cancer and immunity Hijacked in cancer: the KMT2 (MLL) family of methyltransferases Getting up to speed with transcription elongation by RNA polymerase II Chromatin signatures of cancer Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis.NMR Fragment Screening Hit Induces Plasticity of BRD7/9 Bromodomains BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects Emerging concepts of epigenetic dysregulation in hematological malignancies Epigenetic determinants of metastasis aBETting therapeutic resistance by Wnt signaling The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis Targeting bromodomains: epigenetic readers of lysine acetylation Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation The mechanisms behind the therapeutic activity of BET bromodomain inhibition Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability Functions of BET proteins in erythroid gene expression Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

P2860

Q21246017-F4A48424-EACF-4323-BB30-5855CF8E236D Q24305395-1FE3EFD5-9692-411E-A8A2-02D295CE30EE Q24315005-940C746C-8FCE-4462-9697-FEF40EBC36CC Q24337204-712BD44B-3BAD-4E10-BB4A-8B0E3BFEFF79 Q26739748-7D949FD4-B8A7-49C5-B2B0-2D6685E80B14 Q26744080-DB557CD3-AE2B-4EE6-B6A3-DF984DCB9DAF Q26747745-E4F1534C-2975-4772-806E-E8D02BFA44B7 Q26753387-1DB35823-FE24-46FF-8D93-C776D7B0A9F7 Q26766093-C1D322E1-F380-44A9-86F7-C6D19C897845 Q26766149-9FEDAE3F-1A11-44E4-9A35-A38FD4C7EA2B Q26775423-313C0AC0-2524-4A7D-893C-0790587FDD91 Q26779821-FEF511C5-86B7-4669-AACE-B230E20BADDA Q26782507-06FE92E2-C34B-4B6C-8667-1619F25DD971 Q26785379-342A55F3-1EE7-4D47-BE63-DA69FF73537F Q26796369-1A85B7F1-4494-4D6B-B585-7DBE536054D3 Q26826804-EAE3A6DC-6D68-4F06-9213-17F5AB3A5A42 Q26849595-6447D079-7804-42EF-A675-9A6C915F6158 Q26859355-BA3A2227-D20D-42A7-B5B1-40A405AC7E92 Q26861020-BB5BC949-CB7B-4A9B-971D-BA341C782C36 Q26861197-A8E3060E-E164-486F-9F7D-E73E5CC84E4F Q26865149-7FEDADC6-DB9F-411A-A23E-02EA3DEB0754 Q26999888-9F823DBF-77F6-4049-A4E8-C56535760CE6 Q27006839-E7B9A070-92E0-482A-A641-E34039BDCB26 Q27023288-7C378A7E-446F-4843-8911-F0485EF9D96B Q27024162-08F97686-789E-45F1-B32C-8845EA10599D Q27304386-7553C635-C17F-4E3A-B01B-9906E377E6C2 Q27308738-01FA28A8-416D-46E3-BC5E-3B019F231347 Q27704896-DE8D05D1-7CF1-43D7-AC70-D605F27D2152 Q28066765-10CBB4AE-EB8B-4074-88FA-9741D1A6ED74 Q28074522-ECD6BE28-DB60-4803-81DB-5E14C0A6279A Q28079377-4D01501D-A865-46CA-9474-80FDCFFA5C7F Q28081557-5264A430-81D1-418E-A34B-4DD6146BBF0E Q28088295-C33862C8-9B6C-42FC-93A3-6CB491330DD9 Q28115805-ECC036AF-47A6-442F-B88D-02A9A36BDABD Q28238635-DCE709CD-8ED8-45EE-BE81-0FAA33EF3050 Q28240747-BDB031A3-904A-410E-B1C3-D3AF4F6B2D0A Q28241504-25A00A3D-518B-4634-9BD5-6A4401998FA6 Q28253489-7383A4FC-F457-44F3-A728-EB79DCEBF827 Q28257378-A4955A5A-0D38-4A63-962B-75F82A84B0FB Q28260105-9D6589BF-4EE5-4B41-8036-642D3D22613D

P2860

Selective inhibition of tumor oncogenes by disruption of super-enhancers

http://www.wikidata.org/entity/Q29617301

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Selective inhibition of tumor oncogenes by disruption of super-enhancers

@ast

Selective inhibition of tumor oncogenes by disruption of super-enhancers

@en

type

label

Selective inhibition of tumor oncogenes by disruption of super-enhancers

@ast

Selective inhibition of tumor oncogenes by disruption of super-enhancers

@en

prefLabel

Selective inhibition of tumor oncogenes by disruption of super-enhancers

@ast

Selective inhibition of tumor oncogenes by disruption of super-enhancers

@en

P1433

Q29617301-2553CDCA-CFD2-49B7-BAF1-202861D66A05

P1476

Q29617301-773D6558-E2C0-4507-A336-8898B1E13A6C

P2093

Q29617301-39B20FC7-A46F-4246-AC11-443EED11998F

Q29617301-54EBA71E-35A6-408B-99CA-09C247A03AD1

Q29617301-6E5F2B0E-4E7F-4957-85A7-2D3184AAD878

Q29617301-B0B2CFCA-F4D3-46F6-8787-87D3EE4BC49D

Q29617301-B127618F-AF27-4D89-8BFB-F9EA643B7007

Q29617301-BB3D9896-1A4F-4991-B7D1-EBE453A67236

Q29617301-E4B271F7-108F-4F86-9034-75A0BAAD950D

P2860

Q29617301-01D6CBA4-9CB6-43FC-81DC-071C89B53E8B

Q29617301-05790B6E-5D11-48FB-AD9C-0DF6FD87962B

Q29617301-0ED719D7-4332-46BE-86B6-91D92B78A3C7

Q29617301-0F0E8F78-7FDB-41E8-8ADF-AFE060FA5067

Q29617301-10B314CA-7CB2-4F85-82EE-F3FB52966E35

Q29617301-182E68DA-352F-4079-A2E8-1669AFBD9AF0

Q29617301-18B6C0D4-1B7B-4E0B-98D8-747F397A08AD

Q29617301-1EC05829-44AF-4ACC-9B38-DCDCE543E014

Q29617301-200C2321-E15F-4522-991A-A3A46D2AF42E

Q29617301-206657F8-7AEC-467D-A6C1-7E801DE85925

P304

Q29617301-FA8222F2-F9B0-4854-89EC-785EEEA12994

P31

Q29617301-489DAF15-81E7-4907-881E-91FB0929CE3D

P3181

Q29617301-67308C93-CA96-443C-86B1-438072308E59

P356

Q29617301-37ABEDA4-78B9-4E55-857F-3AFC224E4DC7

P407

Q29617301-9009C0B9-56CE-48CD-882F-FFB033F84494

P433

Q29617301-6881C9D8-1C4D-461B-922C-3FA9702404A8

P478

Q29617301-FD7E7770-E394-4CC7-816C-4274E2BB6A2D

P50

Q29617301-14E58C69-09C4-4EDC-9839-1C9FBCA917AF

Q29617301-9BDCE4BF-E7F8-45C8-A620-9403BB588425

P577

Q29617301-6BBFF47D-F9CA-4206-8052-0D9E35C228E1

P5875

Q29617301-71DBF7D2-13AA-49EA-9B18-6F66BB858517

P698

Q29617301-A08628CD-285E-4C9A-8046-90E0E272ADD8

P932

Q29617301-ECA63E2F-2BB9-479A-B10C-4F0F59F92DED

P3181

P356

J.CELL.2013.03.036

P1433

P1476

Selective inhibition of tumor oncogenes by disruption of super-enhancers

@en

P2093

Ashley Lau

http://www.w3.org/2001/XMLSchema#string

Charles Y Lin

http://www.w3.org/2001/XMLSchema#string

David A Orlando

http://www.w3.org/2001/XMLSchema#string

Heather A Hoke

http://www.w3.org/2001/XMLSchema#string

Jakob Lovén

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Tong Ihn Lee

http://www.w3.org/2001/XMLSchema#string

P2860

The mechanism of release of P-TEFb and HEXIM1 from the 7SK snRNP by viral and cellular activators includes a conformational change in 7SK

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

Model-based analysis of ChIP-Seq (MACS)

Plasma cell differentiation requires the transcription factor XBP-1

Selective inhibition of BET bromodomains

Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells

Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription

A decade of exploring the cancer epigenome - biological and translational implications

P304

320-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

275303

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CELL.2013.03.036

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P50

Christopher R. Vakoc

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236198699

http://www.w3.org/2001/XMLSchema#string

P698

23582323

http://www.w3.org/2001/XMLSchema#string

P932

3760967

http://www.w3.org/2001/XMLSchema#string